BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi’in, Israel.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for BioLineRx Ltd. (BLRX)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
3 days ago | PRNewsWire
2 months ago | PRNewsWire
2 months ago | PRNewsWire
3 months ago | Pulse2
3 months ago | Benzinga
3 months ago | Pulse2
3 months ago | PRNewsWire
4 months ago | PRNewsWire
5 months ago | PRNewsWire